These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 36442662

  • 1. Comparison of Clinical Outcomes Among Different Fixed-Dose Combinations of Long-Acting Muscarinic Antagonists and Long-Acting β2-Agonists in Patients With COPD.
    Weng CF, Wu CC, Wu MH, Lin FJ.
    Chest; 2023 Apr; 163(4):799-814. PubMed ID: 36442662
    [Abstract] [Full Text] [Related]

  • 2. Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies.
    Palli SR, Xie B, Chastek B, Elliott CA, Bengtson LGS.
    J Manag Care Spec Pharm; 2021 Jul; 27(7):810-824. PubMed ID: 33764161
    [Abstract] [Full Text] [Related]

  • 3. Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol.
    Sethi S, Palli SR, Bengtson LGS, Buysman EK, Clark B, Sargent A, Shaikh A, Ferguson GT.
    J Manag Care Spec Pharm; 2023 Jul; 29(7):791-806. PubMed ID: 37133429
    [Abstract] [Full Text] [Related]

  • 4. Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β2-Agonist Plus Inhaled Long-Acting Muscarinic Antagonist vs Inhaled Long-Acting β2-Agonist Plus Inhaled Corticosteroid Fixed-Dose Combinations in COPD A Propensity Score-Inverse Probability of Treatment Weighting Cohort Study.
    Wang MT, Lai JH, Huang YL, Liou JT, Cheng SH, Lin CW, Pan HY, Hsu YJ, Tsai CL.
    Chest; 2021 Oct; 160(4):1255-1270. PubMed ID: 34023320
    [Abstract] [Full Text] [Related]

  • 5. Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.
    Feldman GJ, Sousa AR, Lipson DA, Tombs L, Barnes N, Riley JH, Patel S, Naya I, Compton C, Alcázar Navarrete B.
    Adv Ther; 2017 Nov; 34(11):2518-2533. PubMed ID: 29094315
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol.
    Moretz C, Bengtson LG, Sharpsten L, Koep E, Le L, Tong J, Stanford RH, Hahn B, Ray R.
    Int J Chron Obstruct Pulmon Dis; 2019 Nov; 14():2047-2060. PubMed ID: 31564852
    [Abstract] [Full Text] [Related]

  • 7. Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England.
    Requena G, Czira A, Banks V, Wood R, Tritton T, Castillo CM, Yeap J, Wild R, Compton C, Rothnie KJ, Herth F, Quint JK, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2023 Nov; 18():1431-1444. PubMed ID: 37465818
    [Abstract] [Full Text] [Related]

  • 8. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.
    Maqsood U, Ho TN, Palmer K, Eccles FJ, Munavvar M, Wang R, Crossingham I, Evans DJ.
    Cochrane Database Syst Rev; 2019 Mar 06; 3(3):CD012930. PubMed ID: 30839102
    [Abstract] [Full Text] [Related]

  • 9. Differences in Pulmonary Function Improvement after Once-Daily LABA/LAMA Fixed-Dose Combinations in Patients with COPD.
    Huang WC, Chen CY, Liao WC, Wu BR, Chen WC, Tu CY, Chen CH, Cheng WC.
    J Clin Med; 2022 Dec 01; 11(23):. PubMed ID: 36498738
    [Abstract] [Full Text] [Related]

  • 10. Rates of escalation to triple COPD therapy among incident users of LAMA and LAMA/LABA.
    Hahn B, Hull M, Blauer-Peterson C, Buikema AR, Ray R, Stanford RH.
    Respir Med; 2018 Jun 01; 139():65-71. PubMed ID: 29858004
    [Abstract] [Full Text] [Related]

  • 11. Differences in Real-World Health and Economic Outcomes Among Patients with COPD Treated with Combination Tiotropium/Olodaterol Versus Triple Therapy.
    Palli SR, Frazer M, DuCharme M, Buikema AR, Anderson AJ, Franchino-Elder J.
    J Manag Care Spec Pharm; 2020 Oct 01; 26(10):1363-1374. PubMed ID: 32678719
    [Abstract] [Full Text] [Related]

  • 12. Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies.
    Kerwin E, Ferguson GT, Sanjar S, Goodin T, Yadao A, Fogel R, Maitra S, Sen B, Ayers T, Banerji D.
    Lung; 2017 Dec 01; 195(6):739-747. PubMed ID: 28993871
    [Abstract] [Full Text] [Related]

  • 13. A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease.
    Muraki M, Kunita Y, Shirahase K, Yamazaki R, Hanada S, Sawaguchi H, Tohda Y.
    BMC Pulm Med; 2021 Jan 13; 21(1):26. PubMed ID: 33441146
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of LABA/LAMA fixed-dose combinations approved in the US for the management of COPD.
    Banerji D, Mahler DA, Hanania NA.
    Expert Rev Respir Med; 2016 Jul 13; 10(7):767-80. PubMed ID: 27223863
    [Abstract] [Full Text] [Related]

  • 15. Which LABA/LAMA should be chosen in COPD patients in real life?
    Sposato B, Petrucci E, Serafini A, Lena F, Lacerenza LG, Montagnani A, Alessandri M, Cresti A, Scala R, Rogliani P, Ricci A, Perrella A, Scalese M.
    Pulm Pharmacol Ther; 2021 Dec 13; 71():102076. PubMed ID: 34530132
    [Abstract] [Full Text] [Related]

  • 16. Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation History.
    Sethi S, Clark B, Bengtson LGS, Buysman EK, Palli S, Sargent A, Shaikh A, Ferguson GT.
    Int J Chron Obstruct Pulmon Dis; 2023 Dec 13; 18():625-641. PubMed ID: 37155497
    [Abstract] [Full Text] [Related]

  • 17. Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England.
    Requena G, Czira A, Banks V, Wood R, Tritton T, Castillo C, Yeap J, Wild R, Compton C, Rothnie KJ, Herth FJF, Quint JK, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2023 Dec 13; 18():2039-2054. PubMed ID: 37731774
    [Abstract] [Full Text] [Related]

  • 18. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects.
    Feldman GJ, Edin A.
    Ther Adv Respir Dis; 2013 Dec 13; 7(6):311-9. PubMed ID: 24004659
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective.
    Driessen MT, Whalen J, Seewoodharry Buguth B, Vallejo-Aparicio LA, Naya IP, Asukai Y, Alcázar-Navarrete B, Miravitlles M, García-Río F, Risebrough NA.
    Respir Res; 2018 Nov 20; 19(1):224. PubMed ID: 30458866
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
    Wilson MR, Patel JG, Coleman A, McDade CL, Stanford RH, Earnshaw SR.
    Int J Chron Obstruct Pulmon Dis; 2017 Nov 20; 12():997-1008. PubMed ID: 28392684
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.